ING Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$125M Sell
104,043
-90,462
-47% -$92.4M 0.61% 29
2026
Q1
$179M Buy
194,505
+12,870
+7% +$13M 1.09% 17
2025
Q4
$195M Buy
181,635
+17,912
+11% +$17.1M 1.18% 14
2025
Q3
$125M Buy
163,723
+132,234
+420% +$98.4M 0.68% 29
2025
Q2
$24.5M Sell
31,489
-100,322
-76% -$78M 0.15% 107
2025
Q1
$109M Buy
131,811
+24,475
+23% +$20.4M 0.75% 26
2024
Q4
$82.9M Buy
107,336
+103,034
+2,395% +$85.3M 0.56% 31
2024
Q3
$3.81M Sell
4,302
-114,424
-96% -$103M 0.02% 320
2024
Q2
$107M Buy
118,726
+14,856
+14% +$11.9M 0.64% 26
2024
Q1
$80.8M Buy
103,870
+102,701
+8,785% +$73.1M 0.55% 32
2023
Q4
$681K Sell
1,169
-98,939
-99% -$57.8M 0.01% 499
2023
Q3
$53.8M Sell
100,108
-92,442
-48% -$47.6M 0.47% 43
2023
Q2
$90.3M Buy
192,550
+99,736
+107% +$41.8M 0.68% 26
2023
Q1
$31.9M Sell
92,814
-67,876
-42% -$22.9M 0.31% 65
2022
Q4
$58.8M Buy
160,690
+37,085
+30% +$13.1M 0.59% 35
2022
Q3
$40M Sell
123,605
-24,799
-17% -$7.86M 0.67% 37
2022
Q2
$48.1M Buy
148,404
+22,436
+18% +$6.73M 0.56% 37
2022
Q1
$36.1M Sell
125,968
-21,259
-14% -$5.47M 0.36% 63
2021
Q4
$40.7M Buy
147,227
+79,686
+118% +$20.2M 0.36% 55
2021
Q3
$15.6M Buy
67,541
+1,282
+2% +$316K 0.2% 83
2021
Q2
$15.2M Buy
66,259
+10,795
+19% +$2.17M 0.24% 68
2021
Q1
$10.4M Sell
55,464
-2,787
-5% -$545K 0.21% 72
2020
Q4
$9.84M Buy
58,251
+35,093
+152% +$5.24M 0.22% 74
2020
Q3
$3.43M Buy
23,158
+446
+2% +$69K 0.14% 95
2020
Q2
$3.73M Sell
22,712
-183,113
-89% -$28.1M 0.16% 61
2020
Q1
$28.6M Buy
205,825
+115,482
+128% +$15.9M 1.22% 13
2019
Q4
$11.9M Sell
90,343
-46,865
-34% -$5.43M 0.36% 49
2019
Q3
$15.3M Sell
137,208
-54,886
-29% -$6.11M 0.39% 50
2019
Q2
$21.3M Buy
192,094
+9,594
+5% +$1.13M 0.37% 55
2019
Q1
$23.7M Buy
182,500
+118,495
+185% +$14.4M 0.51% 35
2018
Q4
$7.41M Sell
64,005
-99,750
-61% -$11.1M 0.16% 100
2018
Q3
$17.6M Sell
163,755
-2,386
-1% -$239K 0.3% 62
2018
Q2
$14.2M Sell
166,141
-2,238
-1% -$184K 0.27% 59
2018
Q1
$13M Buy
168,379
+11,060
+7% +$890K 0.24% 66
2017
Q4
$13.3M Sell
157,319
-20,171
-11% -$1.72M 0.22% 62
2017
Q3
$15.2M Buy
177,490
+13,113
+8% +$1.08M 0.29% 67
2017
Q2
$13.5M Sell
164,377
-11,953
-7% -$975K 0.26% 66
2017
Q1
$14.8M Buy
176,330
+71,159
+68% +$5.7M 0.27% 68
2016
Q4
$7.74M Sell
105,171
-23,158
-18% -$1.72M 0.15% 106
2016
Q3
$10.2M Buy
128,329
+1,649
+1% +$132K 0.12% 104
2016
Q2
$9.98M Sell
126,680
-20,533
-14% -$1.55M 0.13% 92
2016
Q1
$10.6M Sell
147,213
-870,985
-86% -$65.9M 0.13% 105
2015
Q4
$85.8M Buy
1,018,198
+2,396
+0.2% +$199K 0.52% 47
2015
Q3
$85M Sell
1,015,802
-106,192
-9% -$8.97M 0.59% 39
2015
Q2
$93.7M Sell
1,121,994
-304,798
-21% -$23.2M 0.51% 43
2015
Q1
$104M Sell
1,426,792
-157,428
-10% -$11.2M 0.52% 40
2014
Q4
$109M Buy
1,584,220
+117,730
+8% +$7.95M 0.51% 37
2014
Q3
$95.1M Sell
1,466,490
-136,206
-8% -$8.62M 0.55% 39
2014
Q2
$99.7M Buy
1,602,696
+194,136
+14% +$11.6M 0.5% 42
2014
Q1
$82.9M Sell
1,408,560
-644,059
-31% -$35.9M 0.44% 49
2013
Q4
$105M Buy
2,052,619
+602,563
+42% +$30.2M 0.53% 43
2013
Q3
$73M Sell
1,450,056
-874,862
-38% -$45.8M 0.37% 65
2013
Q2
$114M Buy
+2,324,918
New +$127M 0.6% 43

Other funds holding LLY

ING Group's LLY Position: Q2 2026 in Review

ING Group reduced its Eli Lilly (LLY) stake by 47% in Q2 2026, selling an estimated $92.4M and leaving 104,043 shares worth $125M. The position accounts for 0.61% of the portfolio, ranked #29.

ING Group first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. The position peaked at $195M in Q4 2025. 4,593 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • ING Group held 104,043 shares of Eli Lilly worth $125M as of Q2 2026.
  • ING Group sold 90,462 Eli Lilly shares in Q2 2026, an estimated $92.4M.
  • Eli Lilly made up 0.61% of ING Group's portfolio in Q2 2026, its #29 holding.
  • ING Group first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • ING Group's Eli Lilly position peaked at $195M in Q4 2025.
  • 4,593 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.